However, while PD-1/PD-L1 inhibitors are a promising treatment for patients with advanced GC, their response rate is limited and the development of new strategies to maximize the efficacy of ICI is necessary (Kono et al., 2020; Kole et al., 2022). This evidence concerns the gene PDCD1 and gastric cancer.